Experienced in Erythema Nodosum

Liora Harel

Tel Aviv, TA, IL 
Clinical Trials:Currently Recruiting for 3 Trials
Experienced in Erythema Nodosum
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Liora Harel practices in Tel Aviv, Israel. Ms. Harel is rated as an Experienced expert by MediFind in the treatment of Erythema Nodosum. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Rheumatic Fever, and Juvenile Idiopathic Arthritis (JIA).

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Erythema Nodosum.

Gender
Female

Locations

Tel Aviv, TA, Israel
Other Locations
Petah Tiqwa, M, Israel
Ramat Aviv, TA, Israel
59 Tshernichovski Street, Kfar Saba, M 44281, Israel
Et Taiyiba, M, Israel
Petach Tikvah, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

58 Total Publications

Efficacy and safety of ibuprofen and naproxen in the treatment of oligoarticular juvenile idiopathic arthritis: bi-national cohort study.
Efficacy and safety of ibuprofen and naproxen in the treatment of oligoarticular juvenile idiopathic arthritis: bi-national cohort study.
Journal: Immunopharmacology and immunotoxicology
Published: January 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Harel's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile